ES2732317T3 - Material de relleno dermocosmético y usos del mismo para fines estéticos - Google Patents

Material de relleno dermocosmético y usos del mismo para fines estéticos Download PDF

Info

Publication number: ES2732317T3
Authority: ES; Spain
Prior art keywords: use according; composition; bis; cross; nucleic acid
Prior art date: 2014-02-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

ES15711859T

Other languages

English (en)

Spanish (es)

Inventor

Mastelli Laura Cattarini

Mastelli Giulia Cattarini

Mastelli Silvia Cattarini

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

MASTELLI Srl

Original Assignee

MASTELLI Srl

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-02-20

Filing date

2015-02-20

Publication date

2019-11-21

2015-02-20 Application filed by MASTELLI Srl filed Critical MASTELLI Srl

2019-11-21 Application granted granted Critical

2019-11-21 Publication of ES2732317T3 publication Critical patent/ES2732317T3/es

Status Active legal-status Critical Current

2035-02-20 Anticipated expiration legal-status Critical

Links

239000000945 filler Substances 0.000 title claims abstract description 55
239000000463 material Substances 0.000 title claims abstract description 44
239000003431 cross linking reagent Substances 0.000 claims abstract description 34
238000000034 method Methods 0.000 claims abstract description 21
229920000642 polymer Polymers 0.000 claims abstract description 21
238000011282 treatment Methods 0.000 claims abstract description 21
150000007523 nucleic acids Chemical class 0.000 claims abstract description 19
102000039446 nucleic acids Human genes 0.000 claims abstract description 18
108020004707 nucleic acids Proteins 0.000 claims abstract description 18
239000002537 cosmetic Substances 0.000 claims abstract description 12
239000007972 injectable composition Substances 0.000 claims abstract description 12
230000002500 effect on skin Effects 0.000 claims abstract description 10
238000002560 therapeutic procedure Methods 0.000 claims abstract description 7
238000001356 surgical procedure Methods 0.000 claims abstract description 6
241001465754 Metazoa Species 0.000 claims abstract description 5
239000000203 mixture Substances 0.000 claims description 66
239000002157 polynucleotide Substances 0.000 claims description 57
102000040430 polynucleotide Human genes 0.000 claims description 57
108091033319 polynucleotide Proteins 0.000 claims description 57
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 claims description 12
230000037303 wrinkles Effects 0.000 claims description 10
229920001223 polyethylene glycol Polymers 0.000 claims description 9
SHKUUQIDMUMQQK-UHFFFAOYSA-N 2-[4-(oxiran-2-ylmethoxy)butoxymethyl]oxirane Chemical compound C1OC1COCCCCOCC1CO1 SHKUUQIDMUMQQK-UHFFFAOYSA-N 0.000 claims description 7
AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 claims description 7
PLDLPVSQYMQDBL-UHFFFAOYSA-N 2-[[3-(oxiran-2-ylmethoxy)-2,2-bis(oxiran-2-ylmethoxymethyl)propoxy]methyl]oxirane Chemical compound C1OC1COCC(COCC1OC1)(COCC1OC1)COCC1CO1 PLDLPVSQYMQDBL-UHFFFAOYSA-N 0.000 claims description 6
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
239000002202 Polyethylene glycol Substances 0.000 claims description 6
IBVAQQYNSHJXBV-UHFFFAOYSA-N adipic acid dihydrazide Chemical compound NNC(=O)CCCCC(=O)NN IBVAQQYNSHJXBV-UHFFFAOYSA-N 0.000 claims description 6
VYLDEYYOISNGST-UHFFFAOYSA-N bissulfosuccinimidyl suberate Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)C(S(O)(=O)=O)CC1=O VYLDEYYOISNGST-UHFFFAOYSA-N 0.000 claims description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
239000008363 phosphate buffer Substances 0.000 claims description 4
LFKLPJRVSHJZPL-UHFFFAOYSA-N 1,2:7,8-diepoxyoctane Chemical compound C1OC1CCCCC1CO1 LFKLPJRVSHJZPL-UHFFFAOYSA-N 0.000 claims description 3
PGMKGZOHRBZSSQ-UHFFFAOYSA-N 2-[2-(oxiran-2-ylmethoxy)ethenoxymethyl]oxirane Chemical group C1OC1COC=COCC1CO1 PGMKGZOHRBZSSQ-UHFFFAOYSA-N 0.000 claims description 3
XOBTWQWSFMZPNQ-UHFFFAOYSA-N 5-(oxiran-2-ylmethyl)-7-oxabicyclo[4.1.0]heptane Chemical compound C1CCC2OC2C1CC1CO1 XOBTWQWSFMZPNQ-UHFFFAOYSA-N 0.000 claims description 3
239000005977 Ethylene Substances 0.000 claims description 3
150000002019 disulfides Chemical class 0.000 claims description 3
150000002118 epoxides Chemical class 0.000 claims description 3
FEKRFYZGYUTGRY-UHFFFAOYSA-N n'-ethylmethanediimine Chemical compound CCN=C=N FEKRFYZGYUTGRY-UHFFFAOYSA-N 0.000 claims description 3
-1 phenylene-bis- (ethyl) Chemical group 0.000 claims description 3
206010024604 Lipoatrophy Diseases 0.000 claims description 2
206010046543 Urinary incontinence Diseases 0.000 claims description 2
230000001413 cellular effect Effects 0.000 claims description 2
208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 2
230000036244 malformation Effects 0.000 claims description 2
238000002278 reconstructive surgery Methods 0.000 claims description 2
238000010992 reflux Methods 0.000 claims description 2
238000002435 rhinoplasty Methods 0.000 claims description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 6
229920002134 Carboxymethyl cellulose Polymers 0.000 claims 2
239000001768 carboxy methyl cellulose Substances 0.000 claims 2
235000010948 carboxy methyl cellulose Nutrition 0.000 claims 2
239000008112 carboxymethyl-cellulose Substances 0.000 claims 2
239000011780 sodium chloride Substances 0.000 claims 2
239000013543 active substance Substances 0.000 claims 1
239000005547 deoxyribonucleotide Substances 0.000 claims 1
125000002637 deoxyribonucleotide group Chemical group 0.000 claims 1
238000011049 filling Methods 0.000 description 16
239000000499 gel Substances 0.000 description 16
210000003491 skin Anatomy 0.000 description 16
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
238000004132 cross linking Methods 0.000 description 12
239000007924 injection Substances 0.000 description 11
238000002347 injection Methods 0.000 description 11
210000001519 tissue Anatomy 0.000 description 11
230000009471 action Effects 0.000 description 10
230000000694 effects Effects 0.000 description 10
235000019441 ethanol Nutrition 0.000 description 10
229920002674 hyaluronan Polymers 0.000 description 10
239000002773 nucleotide Substances 0.000 description 10
125000003729 nucleotide group Chemical group 0.000 description 10
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 9
229960003160 hyaluronic acid Drugs 0.000 description 9
238000003756 stirring Methods 0.000 description 8
239000000017 hydrogel Substances 0.000 description 7
238000002316 cosmetic surgery Methods 0.000 description 6
239000000546 pharmaceutical excipient Substances 0.000 description 6
238000007920 subcutaneous administration Methods 0.000 description 6
239000000126 substance Substances 0.000 description 6
239000003981 vehicle Substances 0.000 description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 5
239000000872 buffer Substances 0.000 description 5
239000000243 solution Substances 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
210000004207 dermis Anatomy 0.000 description 4
239000003814 drug Substances 0.000 description 4
239000007943 implant Substances 0.000 description 4
239000002245 particle Substances 0.000 description 4
239000000843 powder Substances 0.000 description 4
230000008569 process Effects 0.000 description 4
239000000047 product Substances 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
206010020751 Hypersensitivity Diseases 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
230000032683 aging Effects 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
230000001815 facial effect Effects 0.000 description 3
239000007863 gel particle Substances 0.000 description 3
238000002513 implantation Methods 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
230000008929 regeneration Effects 0.000 description 3
238000011069 regeneration method Methods 0.000 description 3
239000002904 solvent Substances 0.000 description 3
ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 2
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
206010040925 Skin striae Diseases 0.000 description 2
208000031439 Striae Distensae Diseases 0.000 description 2
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
229960000583 acetic acid Drugs 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
208000026935 allergic disease Diseases 0.000 description 2
230000003712 anti-aging effect Effects 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
235000006708 antioxidants Nutrition 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
230000006399 behavior Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
238000010382 chemical cross-linking Methods 0.000 description 2
229920006037 cross link polymer Polymers 0.000 description 2
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
238000009826 distribution Methods 0.000 description 2
230000007071 enzymatic hydrolysis Effects 0.000 description 2
238000006047 enzymatic hydrolysis reaction Methods 0.000 description 2
210000001508 eye Anatomy 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
230000005226 mechanical processes and functions Effects 0.000 description 2
230000000399 orthopedic effect Effects 0.000 description 2
206010033675 panniculitis Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
229920001296 polysiloxane Polymers 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000009759 skin aging Effects 0.000 description 2
210000004872 soft tissue Anatomy 0.000 description 2
210000004304 subcutaneous tissue Anatomy 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
206010003694 Atrophy Diseases 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
208000032544 Cicatrix Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
241000238424 Crustacea Species 0.000 description 1
241000195493 Cryptophyta Species 0.000 description 1
ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
230000000970 DNA cross-linking effect Effects 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
206010057249 Phagocytosis Diseases 0.000 description 1
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
239000012891 Ringer solution Substances 0.000 description 1
206010040799 Skin atrophy Diseases 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
208000031737 Tissue Adhesions Diseases 0.000 description 1
229930003268 Vitamin C Natural products 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
230000037444 atrophy Effects 0.000 description 1
239000003899 bactericide agent Substances 0.000 description 1
229960005274 benzocaine Drugs 0.000 description 1
230000001588 bifunctional effect Effects 0.000 description 1
229920002988 biodegradable polymer Polymers 0.000 description 1
239000004621 biodegradable polymer Substances 0.000 description 1
238000006065 biodegradation reaction Methods 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
210000001217 buttock Anatomy 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
230000032677 cell aging Effects 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
235000017471 coenzyme Q10 Nutrition 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
239000003086 colorant Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
238000010908 decantation Methods 0.000 description 1
230000007547 defect Effects 0.000 description 1
GYZLOYUZLJXAJU-UHFFFAOYSA-N diglycidyl ether Chemical class C1OC1COCC1CO1 GYZLOYUZLJXAJU-UHFFFAOYSA-N 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000007515 enzymatic degradation Effects 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
229960003180 glutathione Drugs 0.000 description 1
235000003969 glutathione Nutrition 0.000 description 1
239000012456 homogeneous solution Substances 0.000 description 1
239000003906 humectant Substances 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
239000011872 intimate mixture Substances 0.000 description 1
229960004194 lidocaine Drugs 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
229960002409 mepivacaine Drugs 0.000 description 1
INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
238000007431 microscopic evaluation Methods 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
230000000116 mitigating effect Effects 0.000 description 1
239000000178 monomer Substances 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
150000002972 pentoses Chemical class 0.000 description 1
230000002688 persistence Effects 0.000 description 1
230000008782 phagocytosis Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000003186 pharmaceutical solution Substances 0.000 description 1
229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
239000002861 polymer material Substances 0.000 description 1
239000004926 polymethyl methacrylate Substances 0.000 description 1
230000001376 precipitating effect Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
238000000746 purification Methods 0.000 description 1
IGFXRKMLLMBKSA-UHFFFAOYSA-N purine Chemical compound N1=C[N]C2=NC=NC2=C1 IGFXRKMLLMBKSA-UHFFFAOYSA-N 0.000 description 1
230000001172 regenerating effect Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
231100000241 scar Toxicity 0.000 description 1
230000037387 scars Effects 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
210000004927 skin cell Anatomy 0.000 description 1
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
229960002372 tetracaine Drugs 0.000 description 1
GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
229940113082 thymine Drugs 0.000 description 1
230000001228 trophic effect Effects 0.000 description 1
229940035893 uracil Drugs 0.000 description 1
235000019154 vitamin C Nutrition 0.000 description 1
239000011718 vitamin C Substances 0.000 description 1
230000004580 weight loss Effects 0.000 description 1
230000037373 wrinkle formation Effects 0.000 description 1
229940075420 xanthine Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/606—Nucleosides; Nucleotides; Nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/91—Injection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/34—Materials or treatment for tissue regeneration for soft tissue reconstruction

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Transplantation (AREA)
Medicinal Chemistry (AREA)
Oral & Maxillofacial Surgery (AREA)
Birds (AREA)
Dispersion Chemistry (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Gerontology & Geriatric Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Cosmetics (AREA)
Compositions Of Macromolecular Compounds (AREA)

ES15711859T 2014-02-20 2015-02-20 Material de relleno dermocosmético y usos del mismo para fines estéticos Active ES2732317T3 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
ITMI20140248		2014-02-20
PCT/IB2015/051302 WO2015125117A1 (fr)	2014-02-20	2015-02-20	Produit de comblement dermocosmétique et utilisation de celui-ci à des fins esthétiques

Publications (1)

Publication Number	Publication Date
ES2732317T3 true ES2732317T3 (es)	2019-11-21

Family

ID=50624958

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES15711859T Active ES2732317T3 (es)	2014-02-20	2015-02-20	Material de relleno dermocosmético y usos del mismo para fines estéticos

Country Status (5)

Country	Link
EP (1)	EP3107587B1 (fr)
ES (1)	ES2732317T3 (fr)
PL (1)	PL3107587T3 (fr)
TR (1)	TR201909270T4 (fr)
WO (1)	WO2015125117A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP6660469B2 (ja) *	2015-11-24	2020-03-11	ビーエムアイコリアカンパニーリミテッド	ヒアルロン酸誘導体およびｄｎａ分画物が含まれているヒアルロン酸注射用組成物およびその利用
US10058502B2 (en)	2015-12-31	2018-08-28	L'oreal	Nail polish compositions
KR101722181B1 (ko) *	2016-07-06	2017-03-31	주식회사 리온메디코스	PDRN(Polydeoxyribonucleotide)을 포함하는 화장품 조성물
KR101866312B1 (ko) *	2016-07-15	2018-06-11	주식회사 글랜젠	생체 내 지속성 및 항산화 작용이 향상된 폴리디옥시리보뉴클레오티드계 진피 충전재 조성물 및 이의 제조방법
KR101710615B1 (ko) *	2016-09-07	2017-02-27	주식회사 파마리서치프로덕트	생착률을 증가시킨 이식용 진피층 및 이의 제조 방법
AU2018248418A1 (en) *	2017-04-05	2019-11-21	Gelesis, Llc	Improved superabsorbent materials and methods of production thereof
KR102017741B1 (ko) *	2017-12-01	2019-09-03	주식회사 리엔젠	비타민 c 유도체를 고정화한 폴리감마 글루탐산계 진피 충전제 조성물 및 그 제조방법
KR102833738B1 (ko) *	2023-03-22	2025-07-14	한준	애교 살 볼륨 조성물 및 이를 이용한 특수 메이크업 방법
KR102673797B1 (ko) *	2023-03-28	2024-06-10	주식회사 파마리서치바이오	핵산 및 칼슘 하이드록실아파타이트를 포함하는 필러 조성물
KR102814689B1 (ko) *	2023-12-15	2025-05-29	주식회사 파마리서치	Dna 단편 혼합물 및 다가 알코올을 포함하는 조직 수복용 생체 재료 조성물
KR102907955B1 (ko) *	2025-06-26	2026-01-06	주식회사 제이투케이바이오	프리지아에서 분리한 락토바실러스 플란타럼 j2k-815 (kctc 16266bp) 균주 유래의 pdrn 및 이를 이용한 피부 미백용 화장료 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2632186B1 (fr) *	1988-06-03	1992-03-13	Fabre Pierre Cosmetique	Compositions dermatocosmetologiques pour le traitement de la senescence cutanee et la prevention des rides
FR2909560B1 (fr) *	2006-12-06	2012-12-28	Fabre Pierre Dermo Cosmetique	Gel d'acide hyaluronique pour injection intradermique
IT1401218B1 (it) *	2010-07-14	2013-07-12	Mastelli S R L	Composizione ad attivita' bio-rigenerativa, riparativa ed eutrofizzante.

2015
- 2015-02-20 EP EP15711859.7A patent/EP3107587B1/fr active Active
- 2015-02-20 WO PCT/IB2015/051302 patent/WO2015125117A1/fr not_active Ceased
- 2015-02-20 PL PL15711859T patent/PL3107587T3/pl unknown
- 2015-02-20 TR TR2019/09270T patent/TR201909270T4/tr unknown
- 2015-02-20 ES ES15711859T patent/ES2732317T3/es active Active

Also Published As

Publication number	Publication date
WO2015125117A1 (fr)	2015-08-27
TR201909270T4 (tr)	2019-07-22
EP3107587A1 (fr)	2016-12-28
EP3107587B1 (fr)	2019-03-27
PL3107587T3 (pl)	2019-09-30

Publication	Publication Date	Title
ES2732317T3 (es)	2019-11-21	Material de relleno dermocosmético y usos del mismo para fines estéticos
ES2538999T3 (es)	2015-06-25	Hidrogel cohesivo monofásico biodegradable
JP6143269B2 (ja)	2017-06-07	自己組織化複合超小型ペプチドポリマーヒドロゲル
JP5657545B2 (ja)	2015-01-21	注射用容器内で架橋した注射用ヒドロゲルの調製方法
ES2941652T3 (es)	2023-05-24	Composición de ácido hialurónico
ES2647227T3 (es)	2017-12-20	Método para reticular ácido hialurónico; método para preparar un hidrogel inyectable; hidrogel obtenido; uso del gel obtenido
ES2563160T3 (es)	2016-03-11	Geles viscoelásticos como nuevas cargas
EP3574901B1 (fr)	2022-01-26	Dispositify d'injection contenant une composition de l'acide hyaluronique et du chlorhydrate de mépivacaïne
CN102196805B (zh)	2013-10-16	透明质酸或其盐之一、多元醇和利多卡因的热灭菌的注射型组合物
JP6827108B2 (ja)	2021-02-10	皮膚充填剤用途のためのコアセルベートヒアルロナンヒドロゲル
JP2010511454A5 (ja)	2013-07-11	皮内注射用ヒアルロン酸ゲル移植片
RU2009125201A (ru)	2011-01-20	Гель гиалуроновой кислоты для внутрикожной инъекции
TW201620496A (zh)	2016-06-16	具有改良抗性之多糖軟組織充填劑
ES2632456T3 (es)	2017-09-13	Ácido hialurónico reticulado, proceso para la preparación del mismo y uso del mismo en el campo estético
JP2010036032A (ja)	2010-02-18	高い残留性及び容量を与える高い能力を有する注入可能なヒドロゲル
ES2642680T3 (es)	2017-11-17	Síntesis de un gel de fases múltiples inyectable que contenga ácido hialurónico monofásico reticulado y libre y ácido hialurónico bifásico combinado con hidroxiapatita con inhibidor de hialuronidasa microencapsulado
JP2014510590A (ja)	2014-05-01	フィラー製品および少なくとも１つの生体吸収性および生分解性シリカベースの材料を含む組成物
Shirbhate et al.	2022	Injectable and self-invigorating hydrogel applications in dentistry and periodontal regeneration: A literature review
CN115335414A (zh)	2022-11-11	高分子量美容组合物
KR20220105599A (ko)	2022-07-27	히알루론산, 폴리에틸렌글리콜 및 실리콘 함유 성분을 포함하는 생체적합성 하이드로겔
WO2021018377A1 (fr)	2021-02-04	Composition cosmétique à charge combinée et effet régénérateur cutané
CN111315813B (zh)	2023-01-10	基于交联的糖胺聚糖的可吸收可植入装置及其制备方法
US10588922B2 (en)	2020-03-17	Method for preparing an injectable cross-linked hydrogel, hydrogel obtained; and use of the obtained hydrogel
EP3416652B1 (fr)	2020-07-22	Composition injectable; procédé de préparation de ladite composition; utilisation de ladite composition
HK40094101A (zh)	2024-01-12	羟磷灰石钙粒子及其用途